Breaking News Instant updates and real-time market news.

ABT

Abbott

$53.70

1.545 (2.96%)

, ALR

Alere

$49.27

0.375 (0.77%)

13:36
09/28/17
09/28
13:36
09/28/17
13:36

Abbott, Alere agree to divestitures in settlement with FTC

Abbott Laboratories (ABT) and Alere (ALR) have agreed to a divestiture of two point-of-care medical device products line in order to settle Federal Trade Commission charges that Abbott's proposed $8.3B acquisition of Alere will cause harm to competition, the FTC said in a statement. Under the terms of a proposed settlement with the FTC, the companies will divest the rights and assets, including all related intellectual property, manufacturing technology, and confidential business information as follows" Alere's blood gas testing system will be divested to Siemens Aktiengelsellschaft; Alere's cardiac marker testing system will be divested to Quidel (QDEL). The parties must also divest Alere's two Ottawa, Canada facilities to Siemens, and Alere's San Diego, California facility to Quidel. The settlement requires the parties to complete the divestitures to Siemens and Quidel no more than 30 days after the proposed acquisition is finalized. Reference Link

ABT

Abbott

$53.70

1.545 (2.96%)

ALR

Alere

$49.27

0.375 (0.77%)

SIE

Sierra Health Services

QDEL

Quidel

$41.81

-0.73 (-1.72%)

  • 18

    Oct

ABT Abbott
$53.70

1.545 (2.96%)

09/28/17
BMOC
09/28/17
NO CHANGE
BMOC
Dexcom price target lowered to $62 from $90 at BMO Capital
BMO Capital analyst JoanneK.Wuensch lowered her price target on Dexcom (DXCM) after Abbott (ABT) received FDA approval for a competing product. The analyst says the approval was unexpected, but she says that Dexcom's product is "materially superior." She thinks that the company's "long-term growth story remains intact," and she keeps an Outperform rating on the shares.
09/28/17
COWN
09/28/17
NO CHANGE
Target $64
COWN
Outperform
Dexcom price target lowered to $64 from $90 at Cowen
Cowen analyst Doug Schenkel lowered his price target on Dexcom (DXCM) to $64 from $90 and lowered his estimates to reflect the approval of the Abbott (ABT) Libre, with a dosing claim, at least a year earlier than expected. The claim is important because it is a precursor for CMS reimbursement, said Schenkel. He keeps his Outperform rating on Dexcom pending additional details and based on the magnitude of its glucose monitoring opportunity.
09/28/17
NORL
09/28/17
DOWNGRADE
Target $60
NORL
Market Perform
Dexcom downgraded to Market Perform from Outperform at Northland
Northland analyst Suraj Kalia downgraded Dexom (DXCM) to Market Perform and cut its price target to $60 from $85 following the surprise PMA approval of Abbott's (ABT) Libre flash glucose monitor for a 10-day use. The analyst said Libre received a concomitant nonadjunctive to fingersticks label, which came as a surprise, and removes a key competitive advantage for Dexcom.
09/28/17
WBLR
09/28/17
NO CHANGE
WBLR
Outperform
William Blair sees Dexcom retaining advantage over Abbott
William Blair analyst Margaret Kaczor says that while she didn't think Abbott's (ABT) Libre Flash Glucose Monitoring device would receive a dosing claim given the product's "inferior accuracy," Libre still lacks DexCom's (DXCM) alerts and alarms that proactively protect the patient from glycemic excursions. Libre's dosing may shift the competitive dynamic "modestly in Abbott's favor versus Street expectations," but more importantly, its approval should be market expansive as it creates a new type of glucose monitoring category in the United States, Kaczor tells investors in a research note. The analyst believes DexCom will retain a "material technological and brand advantage." Further, the company has a "rich product pipeline" including its own 10-day G6 sensor that is nearing approval, the analyst adds. She keeps an Outperform rating on Dexcom. Kaczor thinks the stock, at last night's price between $55 and $56, adequately prices in risk of share loss in the category. Dexcom in premarket trading is down 29% to $47.93.
ALR Alere
$49.27

0.375 (0.77%)

06/06/17
ADAM
06/06/17
DOWNGRADE
ADAM
Hold
Alere downgraded to Hold from Buy at Canaccord
09/19/17
PIPR
09/19/17
UPGRADE
Target $50
PIPR
Overweight
Quidel upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Quidel (QDEL) to Overweight and raised his price target for the shares to $50 from $35. The stock can continue to rise as investors digest how accretive the updated Alere (ALR) deal is and become more comfortable with an Abbott (ABT)/Alere deal close, Quirk tells investors in a research note. To reflect the amended deal agreement, the analyst raised his 2018 earnings estimates for Quidel by 64%.
07/18/17
ADAM
07/18/17
UPGRADE
Target $42
ADAM
Buy
Quidel upgraded to Buy from Hold at Canaccord
Canaccord analyst Mark Massaro upgraded Quidel (QDEL) to Buy from Hold as it is a beneficial buyer of Alere (ALR) assets. The analyst said the deal doubles the company's revenues, is immediately accretive, was bought at a low multiple to market value, and provides the company with new platforms to add tests on. Massaro raised his price target to $42 from $25 on Quidel shares.
06/28/17
RBCM
06/28/17
NO CHANGE
RBCM
RBC sees competing bid for Spectranetics as unlikely
RBC Capital analyst Glenn Novarro believes a competing bid for Spectranetics (SPNC) is unlikely and that Philips' (PHG) offer "signals a high probability of an on-time approval." The analyst notes Boston Scientific (BSX) is already developing a drug-eluting stent and a drug-coated balloon for peripheral artery disease and that Abbott (ABT) is integrating St. Jude while also soon closing its buyout of Alere (ALR).
SIE Sierra Health Services

QDEL Quidel
$41.81

-0.73 (-1.72%)

09/19/17
LEHM
09/19/17
NO CHANGE
Target $45
LEHM
Overweight
Quidel price target raised to $45 from $39 at Barclays
Barclays analyst Jack Meehan raised his price target for Quidel shares to $45 citing improved accretion and visibility following the company's amended agreement to acquire the Triage and BNP businesses. The analyst continues to support the acquisition and keeps an Overweight rating on Quidel. Piper Jaffray this morning upgraded the shares.
07/18/17
WBLR
07/18/17
UPGRADE
WBLR
Outperform
Quidel upgraded to Outperform from Market Perform at William Blair
William Blair analyst Brian Weinstein upgraded Quidel to Outperform following the company's acquisition of Alere's Triage assets. Canaccord Genuity this morning also upgraded the shares.

TODAY'S FREE FLY STORIES

MDGL

Madrigal Pharmaceuticals

$47.52

0.51 (1.08%)

08:42
10/19/17
10/19
08:42
10/19/17
08:42
Initiation
Madrigal Pharmaceuticals initiated  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

RMBL

RumbleON

$9.30

0.3 (3.33%)

08:42
10/19/17
10/19
08:42
10/19/17
08:42
Syndicate
RumbleON 2.91M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

XPO

XPO Logistics

$64.76

0.12 (0.19%)

08:40
10/19/17
10/19
08:40
10/19/17
08:40
Hot Stocks
Department of Defense boosts XPO contract by $139.5M to $2.32B »

The Department of Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

GEMP

Gemphire Therapeutics

$9.54

-0.08 (-0.83%)

08:40
10/19/17
10/19
08:40
10/19/17
08:40
Initiation
Gemphire Therapeutics initiated  »

Gemphire Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$37.97

0.48 (1.28%)

08:39
10/19/17
10/19
08:39
10/19/17
08:39
Recommendations
eBay analyst commentary  »

eBay progress…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:39
10/19/17
10/19
08:39
10/19/17
08:39
Hot Stocks
Genuine Parts announces two industrial and automotive acquisitions »

Genuine Parts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

BANR

Banner Corp.

$61.29

0.54 (0.89%)

, PUB

People's Utah Bancorp

$32.85

0.2 (0.61%)

08:38
10/19/17
10/19
08:38
10/19/17
08:38
Conference/Events
People's Utah Bancorp to hold a conference call »

Management discusses…

BANR

Banner Corp.

$61.29

0.54 (0.89%)

PUB

People's Utah Bancorp

$32.85

0.2 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 26

    Oct

  • 09

    Nov

MTG

MGIC Investment

$13.54

0.43 (3.28%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Recommendations
MGIC Investment analyst commentary  »

MGIC Investment price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$153.00

2.62 (1.74%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

IFMK

iFresh

$12.15

-0.1 (-0.82%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Hot Stocks
iFresh announces exclusive agreement with Dragon Seeds »

iFresh announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$7.00

-0.05 (-0.71%)

08:36
10/19/17
10/19
08:36
10/19/17
08:36
Technical Analysis
Technical View: Corbus Pharmaceuticals surges on anabasum Phase 2 results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$12.33

0.01 (0.08%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Hot Stocks
Celestica appoints Mandeep Chawla as CFO »

Celestica announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Hot Stocks
Genuine Parts CEO: Q3 'presented us with both opportunities and challenges' »

Paul Donahue, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Recommendations
American Express analyst commentary  »

American Express guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 08

    Nov

AXP

American Express

$92.08

0.39 (0.43%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Recommendations
American Express analyst commentary  »

American Express price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 08

    Nov

AGEN

Agenus

$4.71

0.04 (0.86%)

, ADRO

Aduro Biotech

$9.55

-0.1 (-1.04%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Conference/Events
William Blair biotech analyst holds an analyst/industry conference call Aduro Biotech »

Biotech Analyst Phipps,…

AGEN

Agenus

$4.71

0.04 (0.86%)

ADRO

Aduro Biotech

$9.55

-0.1 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 24

    Oct

ARNA

Arena Pharmaceuticals

$27.56

0.71 (2.64%)

08:34
10/19/17
10/19
08:34
10/19/17
08:34
Hot Stocks
Arena Pharmaceuticals reports Phase 2 results of ralinepag in hypertension »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VCYT

Veracyte

$9.19

0.29 (3.26%)

08:33
10/19/17
10/19
08:33
10/19/17
08:33
Hot Stocks
Veracyte to present data on Percepta Bronchial Genomic Classifier at CHEST 2017 »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:32
10/19/17
10/19
08:32
10/19/17
08:32
Earnings
Genuine Parts cuts FY17 adjusted EPS view to $4.55-$4.60 from $4.70-$4.75 »

FY17 consensus $4.73.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

08:32
10/19/17
10/19
08:32
10/19/17
08:32
General news
Jobless Claims data reported »

Week of 10/14 Jobless…

ADBE

Adobe

$153.00

2.62 (1.74%)

08:32
10/19/17
10/19
08:32
10/19/17
08:32
Recommendations
Adobe analyst commentary  »

Adobe growth, margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

08:32
10/19/17
10/19
08:32
10/19/17
08:32
General news
Philadelphia Fed Business Outlook Survey General Conditions Index data reported »

October Philadelphia Fed…

W

Wayfair

$67.13

-0.63 (-0.93%)

08:32
10/19/17
10/19
08:32
10/19/17
08:32
Initiation
Wayfair initiated  »

Wayfair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

ADBE

Adobe

$153.00

2.62 (1.74%)

08:31
10/19/17
10/19
08:31
10/19/17
08:31
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

UQM

UQM Technologies

$1.13

-0.01 (-0.88%)

, F

Ford

$12.19

-0.08 (-0.65%)

08:31
10/19/17
10/19
08:31
10/19/17
08:31
Hot Stocks
UQM Technologies to collaborate with Lightning Systems for eQVM program by Ford »

UQM Technologies (UQM)…

UQM

UQM Technologies

$1.13

-0.01 (-0.88%)

F

Ford

$12.19

-0.08 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.